Neuropsychiatry
To help patients with psychiatric and neurological disorders to restore their social integration we offer a variety of products in this area.
Memeantacare®
Memeantacare®
Assessment of cognition using SIB* showed a significantly reduced rate of cognitive decline with Memantcare® versus placebo.
More details
Assessment of cognition using SIB* showed a significantly reduced rate of cognitive decline with Memantcare® versus placebo.
Memantine 10mg film-coated scored tablets
Treatment of patients with Moderate to severe Alzheimer’s disease.
Memantacare should be administrated orally once a day and should be taken at the same time every day with or without food,
The maximum daily dose is 20mg/day. In order to reduce risk of undesirable side effects the maintenance dose is achieved by upward titration of 5mg till 20mg in 4 weeks
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
A carton box containing 1, 2 transparent colorless (Al/PVDC) blisters, each of 10 film coated tablets, Keep out of reach of children.
Related Products
